<unk> , sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is taken by mouth. An estimated 75% of women will have at least one episode and 40%–45% will have two or more episodes in their life-time.<unk>  is a triterpenoid antifungal.<unk>  was approved for medical use in the United States in June 2021. It is the first approved drug in a novel antifungal class.
Ibrexafungerp
Clinatec
Nicogel
Ciltacabtagene autoleucel
Coralmyn
Lisocabtagene maraleucel
Keldur
Idecabtagene vicleucel